Home / Health / Gilead & Merck HIV Pill Shows Promise in Trials
Gilead & Merck HIV Pill Shows Promise in Trials
21 Jul
Summary
- Experimental weekly HIV pill from Gilead and Merck is effective.
- Late-stage trials show the pill keeps the virus suppressed.
- This could be the first once-weekly HIV treatment regimen.
Gilead Sciences and Merck have reported promising outcomes from two late-stage clinical trials for their experimental once-weekly HIV pill. The trials concluded that the drug regimen successfully suppressed the virus in participants.
These findings are crucial for supporting upcoming regulatory filings. If approved, this treatment would represent the first-ever HIV therapy that requires administration only once a week, potentially transforming daily management for individuals living with HIV.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
